Cardiol Therapeutics
CRDL
52 hedge funds and large institutions have $31.3M invested in Cardiol Therapeutics in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
11% more funds holding
Funds holding: 47 → 52 (+5)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0.64% more ownership
Funds ownership: 24.95% → 25.58% (+0.64%)
17% less capital invested
Capital invested by funds: $37.6M → $31.3M (-$6.34M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$759K |
| 2 |
Renaissance Technologies
New York
|
+$687K |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$312K |
| 4 |
Two Sigma Investments
New York
|
+$269K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$229K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$135K |
| 2 |
IA
Integrity Alliance
Urbandale,
Iowa
|
-$96.9K |
| 3 |
Jane Street
New York
|
-$93.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$89.1K |
| 5 |
VF
Virtu Financial
New York
|
-$32K |
CRDL Hedge Fund Activity: Q2 2026 in Review
52 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q2 2026, worth a combined $31.3M — down 17% from $37.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CRDL positions and 6 closed out — a net gain of 6 holders — while 11 added to existing stakes and 10 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $759K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $135K sold.
- 52 institutional investors held Cardiol Therapeutics (CRDL) as of Q2 2026, up from 47 in Q1 2026.
- Funds reported $31.3M of Cardiol Therapeutics stock for Q2 2026, down 17% quarter-over-quarter.
- 12 funds opened new Cardiol Therapeutics positions in Q2 2026 and 6 closed out, a net change of +6 holders.
- The largest Cardiol Therapeutics buyer in Q2 2026 was Ikarian Capital, an estimated $759K added.
- The largest Cardiol Therapeutics seller in Q2 2026 was Knoll Capital Management, an estimated $135K sold.
Based on aggregated 13F filings for Q2 2026.